Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AL 034

Next Previous
Drug Profile

AL 034

Alternative Names: AL-034; JNJ-4964; JNJ-64794964; TQ-A3334

Latest Information Update: 12 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Developer Alios BioPharma; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Antivirals; Immunotherapies
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 07 Dec 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Hepatitis B (In volunteers) (PO, Tablet) in January 2024 (NCT06160895)
  • 10 Nov 2023 Efficacy and adverse event data from the phase II OCEAN cure05 trial presented at the Liver Meeting 2023 74th Annual Meeting of the American Association for the Study of Liver (AASLD-2023)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers, In adults) in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top